牟若菱
Lv21
110 积分
2021-10-21 加入
-
Systemic sclerosis-associated interstitial lung disease
2小时前
已完结
-
Assessment and comparison of the 2023 ACR/EULAR APS criteria with the revised Sapporo criteria
14天前
已完结
-
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
1年前
已完结
-
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
1年前
已完结
-
Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis
2年前
已完结
-
1990—2019年中国胰腺癌发病和死亡情况及其变化趋势分析
2年前
已完结
-
2000—2019年中国胃癌流行病学趋势分析
2年前
已完结
-
Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial
2年前
已完结
-
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
2年前
已完结
-
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy
2年前
已完结